GlassScriptPhysician profile
Philip Gilman
NPI 1164487468
$8,810.89
in general payments reported to CMS, 2019-2025
33 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $313 · 2021: $841 · 2022: $1,493 · 2023: $1,391 · 2024: $2,351 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889 · Education: $41.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,888.55 |
| Education | $41.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,868.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $928.94 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $905.06 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $753.18 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $612.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $494.64 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $357.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $306.10 | 2022-2025 | |
| Redhill Biopharma INC. | $249.52 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Merck Sharp & Dohme LLC | $175.03 | 2019-2024 | Dificid |
| Pfizer INC. | $168.48 | 2020-2025 | |
| Qol Medical, LLC | $147.98 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $121.28 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $111.72 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $72.49 | 2023-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $56.19 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $47.28 | 2021-2022 | |
| Ardelyx, INC. | $44.79 | 2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $42.80 | 2019-2021 | |
| Celltrion USA INC. | $41.38 | 2023-2024 | Yuflyma, Zymfentra |
| Daiichi Sankyo INC. | $34.52 | 2019 | |
| Alfasigma USA, INC. | $33.06 | 2020 | |
| Lilly USA, LLC | $32.29 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $28.63 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $28.28 | 2022 | |
| Laborie Medical Technologies Corp. | $25.43 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $22.26 | 2022 | |
| Capsovision, INC. | $20.46 | 2024 | Capsocam Plus |
| Evoke Pharma, INC. | $18.92 | 2025 | |
| Intra-Sana Laboratories | $16.90 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.71 | 2019 | |
| Vivus LLC | $14.92 | 2019 | |
| Allergan, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Gilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.